Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections.
Via Nova Therapeutics has raised $5.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2021.
Via Nova Therapeutics's investors include Aditum Bio.
Via Nova Therapeutics is headquartered in Oakland, United States.
Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections.
Via Nova Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Via Nova Therapeutics — Funding & Investors." VCBacked, September 15, 2021, https://www.vcbacked.co/company/via-nova-therapeutics. Accessed September 30, 2026.
VCBacked. (2021). Via Nova Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/via-nova-therapeutics
{{cite web |title=Via Nova Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/via-nova-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated